Long-term effectiveness of cladribine in patients previously treated with oral cladribine: a Real-World Evidence analysis using data from the Italian Registry of Multiple Sclerosis (CLARINET-MS)

04/10/2018
23/03/2026
EU PAS number:
EUPAS25783
Study
Finalised
Study identification

EU PAS number

EUPAS25783

Study ID

25784

Official title and acronym

Long-term effectiveness of cladribine in patients previously treated with oral cladribine: a Real-World Evidence analysis using data from the Italian Registry of Multiple Sclerosis (CLARINET-MS)

DARWIN EU® study

No

Study countries

Italy

Study description

No information provided.

Study status

Finalised
Research institutions and networks

Institutions

Merck Healthcare KGaA
Germany
First published:
27/03/2026
Institution Pharmaceutical company

Contact details

Communication Center Merck KGaA

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Date of final study report

Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Merck KGaA
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable